Home Data Calendar Blog

SPRO

Tables

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Common Stock Value 0.05 0.05 0.05 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.00 NA NA

Weighted Average Number Of Diluted Shares Outstanding 52.57 52.53 NA 35.88 32.98 32.61 NA 32.13 29.68 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Weighted Average Number Of Shares Outstanding Basic 52.57 52.53 NA 35.88 32.98 32.61 NA 32.13 29.68 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Weighted Average Number Of Share Outstanding Basic And Diluted NA NA NA NA NA 32.61 NA 32.13 29.68 29.41 NA 21.93 20.63 19.56 19.05 18.66 17.67 17.22 17.74 17.47 14.38 14.37 9.27 0.34 0.33 0.33

Earnings Per Share Basic -0.23 -0.25 0.93 -0.33 -0.87 -1.01 -0.92 -0.70 -0.63 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Earnings Per Share Diluted -0.23 -0.25 0.93 -0.33 -0.87 -1.01 -0.92 -0.70 -0.63 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Earnings Per Share Basic And Diluted NA NA NA NA NA -1.01 -0.92 -0.70 -0.63 -0.66 -0.61 -0.86 -0.85 -1.22 -1.31 -0.95 -0.74 -0.29 -0.60 -0.60 -0.69 -0.74 -1.59 -36.02 -36.21 -21.60

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Revenue From Contract With Customer Excluding Assessed Tax 0.79 0.74 46.35 1.08 0.90 0.25 0.26 0.71 2.11 7.30 0.00 0.04 0.05 0.17 0.70 0.17 0.07 3.81 1.69 0.66 0.46 1.15 0.99 0.60 0.25 0.14

Revenues 2.72 2.07 47.44 2.01 1.99 2.07 2.74 3.06 5.15 7.30 1.91 4.00 1.73 1.70 0.70 4.64 2.16 7.72 1.69 0.66 0.46 1.15 0.99 0.60 0.25 0.14

Operating Expenses 15.61 16.30 21.52 13.84 28.07 32.28 30.25 25.59 23.69 26.70 20.70 23.02 20.20 24.52 29.51 22.63 15.81 13.41 12.78 11.59 10.43 11.97 14.99 10.56 10.41 7.74

Research And Development Expense 9.51 8.98 15.09 7.36 8.17 16.97 17.23 14.44 14.46 18.40 13.21 17.71 15.66 20.44 25.73 18.50 12.03 9.53 9.13 8.46 7.37 8.93 12.50 6.91 7.46 6.00

General And Administrative Expense 6.10 7.32 6.50 6.63 8.05 15.30 13.02 11.15 9.23 8.30 7.50 5.31 4.55 4.09 3.79 4.13 3.78 3.89 3.65 3.13 3.06 3.04 2.49 3.65 2.96 1.74

Operating Income Loss -12.89 -14.23 25.92 -11.83 -26.08 -30.21 -27.50 -22.52 -18.54 -19.40 -18.80 -19.02 -18.48 -22.82 -25.88 -17.98 -13.65 -5.70 -11.08 -10.94 -9.97 -10.82 -14.00 -9.97 -10.16 -7.60

Profit Loss -11.91 -13.27 26.77 -11.68 -28.68 -32.83 -29.24 -22.52 -18.57 -19.42 -18.59 -18.94 -17.50 -23.26 -24.99 -17.72 -13.15 -5.07 -10.60 -10.46 -9.96 -10.64 -13.87 -9.84 -9.76 -6.41

Net Income Loss -11.90 -13.30 NA -11.70 -28.70 -32.80 -29.30 -22.50 -18.60 -19.40 -18.60 -18.90 -17.50 -23.30 -25.00 -17.70 -13.20 -5.10 -10.60 -10.46 -9.96 -10.64 -13.86 -9.84 -9.17 -5.88

Comprehensive Income Net Of Tax -11.91 -13.27 26.77 -11.68 -28.68 -32.83 -29.24 -22.52 -18.57 -19.42 -18.59 -18.95 -17.47 -23.29 -24.99 -17.70 -13.14 -5.04 -10.60 -10.47 -9.94 -10.67 -13.87 -9.84 -9.76 -6.41

Net Income Loss Available To Common Stockholders Basic -11.91 -13.27 119.60 -11.68 -28.68 -32.83 -29.24 -22.52 -18.57 -19.42 -18.59 -18.94 -17.50 -23.81 -24.99 -17.72 -13.15 -5.07 -10.60 -10.46 -9.96 -10.64 -14.77 -12.08 -12.12 -7.13

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Assets 98.89 112.55 124.80 64.48 63.63 145.83 171.07 144.69 119.59 143.44 153.45 157.04 97.55 109.89 106.10 112.51 122.49 124.65 129.01 136.12 72.59 81.06 93.48 31.55 NA NA

Liabilities 44.10 47.71 48.87 31.99 27.70 83.36 82.78 32.80 29.34 24.59 21.41 24.25 23.83 27.47 31.53 19.48 12.82 11.32 13.15 10.57 6.92 6.16 8.52 7.27 NA NA

Liabilities And Stockholders Equity 98.89 112.55 124.80 64.48 63.63 145.83 171.07 144.69 119.59 143.44 153.45 157.04 97.55 109.89 106.10 112.51 122.49 124.65 129.01 136.12 72.59 81.06 93.48 31.55 NA NA

Stockholders Equity 54.78 64.84 75.93 32.48 35.92 62.47 88.29 111.89 90.25 118.85 132.04 132.79 73.71 82.43 74.57 92.68 109.31 112.97 115.50 125.20 65.31 74.54 84.60 -82.19 NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Assets Current 88.35 101.66 113.57 52.89 51.95 132.70 157.87 131.77 106.32 129.49 139.15 142.67 85.29 97.96 95.41 103.97 112.69 115.70 124.22 133.72 70.49 79.74 92.06 26.96 NA NA

Cash And Cash Equivalents At Carrying Value 77.69 96.25 109.11 50.45 45.40 72.11 112.58 112.86 71.56 77.04 85.21 125.24 65.34 64.36 29.73 45.60 71.13 49.40 34.08 40.48 48.72 52.55 87.29 25.37 NA NA

Marketable Securities Current NA NA NA NA NA 49.85 33.82 10.56 27.66 38.63 41.70 2.00 6.02 24.48 52.31 48.26 32.27 57.00 81.36 NA NA NA NA NA NA NA

Prepaid Expense And Other Assets Current 8.57 3.54 3.38 1.49 4.97 8.75 8.83 5.77 4.90 5.19 6.06 7.30 9.16 5.68 4.82 3.68 6.29 7.93 7.48 1.22 1.23 1.22 1.83 1.05 NA NA

Available For Sale Securities Debt Securities NA NA NA NA NA 49.85 33.82 10.56 27.66 38.63 41.70 2.00 6.02 24.48 52.31 48.26 32.27 57.00 81.36 NA NA NA NA NA NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Property Plant And Equipment Gross NA NA 3.62 NA NA NA 3.91 NA NA NA 3.94 NA NA NA 3.79 NA NA NA 3.72 NA NA NA 1.81 NA NA NA

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment NA NA 3.25 NA NA NA 2.88 NA NA NA 2.28 NA NA NA 1.51 NA NA NA 0.83 NA NA NA 0.64 NA NA NA

Property Plant And Equipment Net 0.15 0.26 0.37 0.49 0.62 0.89 1.03 1.21 1.36 1.51 1.67 1.85 1.99 2.16 2.27 2.52 2.69 2.86 2.89 2.19 0.97 1.07 1.16 1.26 NA NA

Other Assets Noncurrent 5.74 5.74 5.74 5.74 5.47 5.93 5.64 5.21 5.21 5.21 5.21 5.21 5.08 4.74 3.52 2.08 2.45 1.42 1.66 NA NA NA NA NA NA NA

Available For Sale Debt Securities Amortized Cost Basis NA NA NA NA NA 49.86 33.82 10.56 27.66 38.64 41.70 2.00 6.00 24.50 52.30 48.24 32.27 57.00 81.39 NA NA NA NA NA NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Liabilities Current 17.32 22.99 21.65 16.23 14.23 69.20 18.67 17.26 12.83 17.76 14.34 17.56 19.01 22.74 26.66 15.06 8.25 6.62 12.32 10.28 6.60 5.83 8.16 6.87 NA NA

Accounts Payable Current 1.31 0.58 0.62 2.58 1.71 4.78 1.10 3.16 1.63 3.83 1.16 2.48 1.56 8.95 4.15 2.52 1.04 0.56 3.60 1.36 0.70 0.98 3.47 2.01 NA NA

Other Accrued Liabilities Current 0.16 0.17 0.21 0.21 0.52 1.06 1.24 1.28 0.20 0.30 0.22 0.84 0.39 0.43 0.41 0.55 0.54 0.64 0.43 0.51 0.38 0.49 0.30 0.25 NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Operating Lease Liability Noncurrent 4.41 4.68 4.96 5.22 5.47 5.73 5.97 6.19 6.43 6.66 6.89 6.50 4.62 4.52 4.62 NA NA NA NA NA NA NA NA NA NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Stockholders Equity 54.78 64.84 75.93 32.48 35.92 62.47 88.29 111.89 90.25 118.85 132.04 132.79 73.71 82.43 74.57 92.68 109.31 112.97 115.50 125.20 65.31 74.54 84.60 -82.19 NA NA

Common Stock Value 0.05 0.05 0.05 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.00 NA NA

Additional Paid In Capital Common Stock 493.79 491.93 489.76 473.09 464.86 462.74 455.72 450.08 405.92 415.95 409.72 391.88 313.86 305.11 273.97 NA NA NA 254.01 NA NA NA NA NA NA NA

Retained Earnings Accumulated Deficit -439.06 -427.14 -413.88 -440.65 -428.97 -400.29 -367.46 -338.22 -315.70 -297.13 -277.71 -259.12 -240.19 -222.69 -199.43 -174.44 -156.72 -143.57 -138.50 -127.90 -117.44 -107.48 -96.84 -82.19 NA NA

Accumulated Other Comprehensive Income Loss Net Of Tax NA NA NA NA NA -0.01 -0.00 -0.00 -0.00 -0.00 -0.01 0.00 0.01 -0.02 0.02 0.02 0.01 0.00 -0.03 NA NA NA NA NA NA NA

Stock Issued During Period Value New Issues NA NA 3.90 6.13 0.58 3.63 2.47 1.10 0.00 4.12 15.30 46.40 7.27 8.96 5.50 0.04 8.25 1.52 NA NA NA NA NA NA NA NA

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 1.86 2.17 2.50 2.11 1.32 3.20 2.93 2.33 2.16 2.01 1.36 1.20 1.21 1.11 0.93 0.98 0.93 0.93 0.77 0.70 0.66 0.61 NA NA NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Net Cash Provided By Used In Operating Activities -18.56 -12.85 44.48 -0.96 -23.03 -28.22 -27.35 -4.95 -16.57 -15.48 -16.38 -21.26 -24.90 -23.33 -17.37 -9.66 -12.07 -10.92 -13.51 -5.51 -8.64 -11.96 -12.74 -10.52 NA NA

Net Cash Provided By Used In Investing Activities NA NA 0.00 -0.13 50.00 -16.06 -23.27 17.02 10.92 3.00 -39.74 3.95 18.48 27.78 -4.10 -15.89 24.84 24.67 7.29 -72.62 5.00 -22.82 NA NA NA NA

Net Cash Provided By Used In Financing Activities NA NA 14.18 6.13 -53.68 3.81 50.35 29.22 0.17 4.31 16.09 77.22 7.39 30.19 5.60 0.01 8.96 1.57 -0.18 69.90 NA NA 74.68 -0.41 NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Net Cash Provided By Used In Operating Activities -18.56 -12.85 44.48 -0.96 -23.03 -28.22 -27.35 -4.95 -16.57 -15.48 -16.38 -21.26 -24.90 -23.33 -17.37 -9.66 -12.07 -10.92 -13.51 -5.51 -8.64 -11.96 -12.74 -10.52 NA NA

Net Income Loss -11.90 -13.30 NA -11.70 -28.70 -32.80 -29.30 -22.50 -18.60 -19.40 -18.60 -18.90 -17.50 -23.30 -25.00 -17.70 -13.20 -5.10 -10.60 -10.46 -9.96 -10.64 -13.86 -9.84 -9.17 -5.88

Profit Loss -11.91 -13.27 26.77 -11.68 -28.68 -32.83 -29.24 -22.52 -18.57 -19.42 -18.59 -18.94 -17.50 -23.26 -24.99 -17.72 -13.15 -5.07 -10.60 -10.46 -9.96 -10.64 -13.87 -9.84 -9.76 -6.41

Depreciation Depletion And Amortization 0.11 0.11 0.13 0.26 0.29 0.19 0.19 0.15 0.15 0.16 0.19 0.19 0.19 0.19 -0.11 0.49 0.19 0.18 0.14 0.08 0.09 0.10 0.10 0.09 0.08 0.09

Increase Decrease In Accounts Payable 0.73 -0.03 -1.97 0.87 -3.07 3.68 -2.06 1.53 -2.21 2.69 -1.32 0.91 -7.39 4.82 1.60 1.49 0.48 -3.01 2.17 0.66 -0.28 -2.47 2.46 -0.23 0.20 -0.08

Share Based Compensation 1.86 2.17 2.50 2.11 1.32 3.20 2.93 2.33 2.16 2.01 1.36 1.20 1.21 1.11 0.93 0.98 0.93 0.93 0.77 0.70 0.66 0.61 0.37 0.93 0.06 0.06

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Net Cash Provided By Used In Investing Activities NA NA 0.00 -0.13 50.00 -16.06 -23.27 17.02 10.92 3.00 -39.74 3.95 18.48 27.78 -4.10 -15.89 24.84 24.67 7.29 -72.62 5.00 -22.82 NA NA NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Net Cash Provided By Used In Financing Activities NA NA 14.18 6.13 -53.68 3.81 50.35 29.22 0.17 4.31 16.09 77.22 7.39 30.19 5.60 0.01 8.96 1.57 -0.18 69.90 NA NA 74.68 -0.41 NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31

Revenues 2.72 2.07 47.44 2.01 1.99 2.07 2.74 3.06 5.15 7.30 1.91 4.00 1.73 1.70 0.70 4.64 2.16 7.72 1.69 0.66 0.46 1.15 0.99 0.60 0.25 0.14

Grant,, Department Of Defense Congressionally Directed Medical Research Programs And Joint Warfighter Medical Research Program NA NA NA 0.10 0.10 0.90 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Grant,, Department Of Defense Congressionally Directed Medical Research Programs And Joint Warfighter Medical Research Program NA NA NA NA NA 0.90 1.20 1.50 1.10 0.60 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

S P R Two Zero Six, Niaid 0.90 0.90 0.70 0.30 0.40 0.30 0.30 0.10 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Grant, Biomedical Advanced Research And Development Authority 1.00 0.50 0.30 0.50 0.70 0.70 1.00 0.70 0.00 6.30 1.30 3.80 1.60 1.20 2.70 4.20 1.50 3.60 1.20 0.20 NA NA NA NA NA NA

Grant, Department Of Defense Congressionally Directed Medical Research Programs And Joint Warfighter Medical Research Program NA NA NA NA 0.10 NA NA 0.00 0.00 0.60 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Revenue From Contract With Customer Excluding Assessed Tax 0.79 0.74 46.35 1.08 0.90 0.25 0.26 0.71 2.11 7.30 0.00 0.04 0.05 0.17 0.70 0.17 0.07 3.81 1.69 0.66 0.46 1.15 0.99 0.60 0.25 0.14

Research And Development Services Related To Upcoming Milestones, Gsk Spa 0.00 19.00 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Everest License Agreement NA NA -0.10 0.00 0.80 NA 0.00 0.50 0.80 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Pfizer License And Share Purchase Agreements 0.30 0.20 0.30 1.10 0.10 0.20 0.20 0.20 1.40 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Plots across concepts

IncomeStatement

Operating Income Loss

Expenses

Other Nonoperating Income Expense

Balance Sheet

Operating Lease Right Of Use Asset

Assets

Property Plant And Equipment Net

Current Assets

Prepaid Expense And Other Assets Current

NonCurrent Assets

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

Property Plant And Equipment Net

Liabilities

Derivative Liabilities

Current Liabilities

Other Accrued Liabilities Current

Stockholders Equity

Retained Earnings Accumulated Deficit

CashFlow

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

Net Cash Provided By Used In Operating Activities

Shares

Weighted Average Number Of Share Outstanding Basic And Diluted

OperatingLeaseLiability

Operating Lease Liability Current

NonoperatingIncomeExpense

Other Nonoperating Income Expense

LesseeOperatingLeaseLiabilityPaymentsDue

Lessee Operating Lease Liability Undiscounted Excess Amount

Line plots across dimensions of each concept

us-gaap:SharesOutstanding
us-gaap:StatementEquityComponents
(None,)

Shares Outstandingus-gaap: Statement Equity Components

TTM Greenblatt ROC
_
(None,)

T T M Greenblatt R O C_

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:TypeOfArrangement
(None,)

Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Type Of Arrangement

us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:Range, us-gaap:TypeOfArrangement
('us-gaap:Grant', None, 'spro:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramsAndJointWarfighterMedicalResearchProgram')

Revenuesus-gaap: Product Or Service, us-gaap: Range, us-gaap: Type Of Arrangement

us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)

Stockholders Equityus-gaap: Statement Equity Components

us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass
(None,)

Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Asset Class

us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType
(None,)

Property Plant And Equipment Grossus-gaap: Property Plant And Equipment By Type

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FairValueByAssetClass
(None,)

Available For Sale Debt Securities Amortized Cost Basisus-gaap: Fair Value By Asset Class

us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)

Stockholders Equityus-gaap: Statement Equity Components

us-gaap:StockIssuedDuringPeriodValueNewIssues
us-gaap:StatementEquityComponents
(None,)

Stock Issued During Period Value New Issuesus-gaap: Statement Equity Components

us-gaap:StockIssuedDuringPeriodValueNewIssues
us-gaap:TypeOfArrangement
(None,)

Stock Issued During Period Value New Issuesus-gaap: Type Of Arrangement

us-gaap:ShareBasedCompensation
us-gaap:IncomeStatementLocation
(None,)

Share Based Compensationus-gaap: Income Statement Location

us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:Range, us-gaap:TypeOfArrangement
('us-gaap:Grant', None, 'spro:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramsAndJointWarfighterMedicalResearchProgram')

Revenuesus-gaap: Product Or Service, us-gaap: Range, us-gaap: Type Of Arrangement

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:TypeOfArrangement
(None,)

Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Type Of Arrangement